The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).
Axel Grothey
Consultant or Advisory Role - Bayer (U); Genentech (U); ImClone Systems (U); Roche (U)
Research Funding - Bayer; Daiichi Sankyo; Genentech
Josep Tabernero
No relevant relationships to disclose
Philippe Rougier
Consultant or Advisory Role - Merck; Sanofi ; SERVIER
Honoraria - Merck; Novartis; Pfizer; Sanofi
Research Funding - Roche
Shaila Ballal
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Heidi Crane
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Mark D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly